S-ketamine is one of 238 small molecule programs targeting Cognitive impairment. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
279 competitors in Cognitive Impairment
Actos
Farxiga
S-ketamine
Provigil
Xarelto
Aquasol E
Viagra
Donepezil Hydrochloride
Statins
Galantamine Hydrobromide
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details